Cationic amphiphilic peptides with cancer-selective toxicity

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 190-194

  Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anticancer peptide; Cationic amphiphilic peptide; Cell penetrating peptide; Drug delivery; Peptidomimetic

Indexed keywords

ALLOFERON; ANTINEOPLASTIC AGENT; CATIONIC AMPHIPHILIC PEPTIDE; CECROPIN; CHLORAMBUCIL; CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MAGAININ 2; MAGAININ DERIVATIVE; MELITTIN; MSI 238; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASCITES; BACTERIAL CELL; CANCER CELL DESTRUCTION; CANCER RESEARCH; CANCER RESISTANCE; CELL SPECIFICITY; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; GENETIC TRANSFECTION; HUMAN; LEUKEMIA; MAMMAL CELL; MEMBRANE DAMAGE; MITOCHONDRION SWELLING; MULTIDRUG RESISTANCE; NONHUMAN; OVARY TUMOR; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; CATIONS; CELL MEMBRANE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PEPTIDES; STATIC ELECTRICITY;

EID: 71749100398     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.043     Document Type: Review

References (76)

1. Arap W., Pasqualini R., and Ruoslahti E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol. 10 (1998) 560-565
2. Baker M.A., Maloy W.L., Zaslof M., and Jacob L.S. Anticancer efficacy of magainin 2 and analogue peptides. Cancer Res. 53 (1993) 3052-3057
3. Bessalle R., Kapitkovsky A., Gorea A., Shalit I., and Fridkin M. All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274 (1990) 151-155
4. Bowdish D.M.E., Davidson D.J., and Hancock R.E.W. A re-evaluation of the role of host defense peptides in mammalian immunity. Curr. Protein Pept. Sci. 6 (2005) 35-51
5. Burdick M.D., Harris A., Reid C.J., Iwamura I., and Hollingsworth M.A. Oligosaccharides expressed on MUC1 by pancreatic and colon tumor cell lines. J. Biol Chem. 272 (1997) 24198-24202
6. Chan S.C., Hui L., and Chen H.M. Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells. Anticancer Res. 18 (1998) 4467-4474
7. Chen H.M., Wang W., Smith D., and Chan S.C. Effects of the anti-bacterial peptide cecropin B and its analogs, cecropin B-1 and B-2, on liposomes, bacteria and cancer cells. Biochim. Biophys. Acta 1336 (1997) 171-179
8. Chen Y., Xu X., Hong S., Chen J., Liub N., Underhill C.B., Creswell K., and Zhang L. RGD-tachyplesin inhibits tumor growth. Cancer Res. 61 (2001) 2434-2438
9. Chen J., Xu X.-M., Underhill C.B., Yang S., Wang L., Cehn Y., Hong S., Creswell K., and Zhang L. Tachyplesin activates the classic complement pathway to kill tumor cells. Cancer Res. 65 (2005) 4614-4622
10. Chernysh S., Kim S.I., Bekker G., Pleskach V.A., Filatova N.A., Anikin V.B., Platonov V.G., and Bulet P. Antiviral and antitumor peptides from insects. Proc. Natl. Acad. Sci. USA 99 (2002) 12628-12632
11. Cory S., and Adams J.M. Matters of life and death: programmed cell death at Cold Spring Harbor. Biochim. Biophys. Acts 1377 (1998) R25-R44
12. Cruciani R.A., Barker J.L., Zasloff M., Chen H.C., and Colamonici O. Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc. Natl. Acad. Sci. USA 88 (1991) 3792-3796
13. Dobrzynska J., Szachowicz-Petelska B., Sulkowski S., and Figaszewski Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem. 276 (2005) 113-119
14. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rammohan R., Ruoslahti E., Bredesen D.E., and Pasqualini R. Anti-cancer activity of targeted proapoptotic peptides. Nat. Med. 5 (1999) 1032-1038
15. Giuliani A., Pirri G., Bozzi A., Di Giulio A., Aschi M., and Rinaldi A.C. Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell. Mol. Life Sci. 65 (2008) 2450-2460
16. Hancock R.E.W., and Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol. 16 (1998) 82-88
17. Hancock R.E.W., and Sahl H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnol. 24 (2006) 1551-1557
18. Haug B.E., Stensen W., Kalaaji M., Rekdal O., and Svendsen J.S. Synthetic antimicrobial peptidomimetics with therapeutic potential. J. Med. Chem. 51 (2008) 4306-4314
19. Henzler-Wildmann K.A., Lee D.K., and Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide LL-37. Biochemistry 42 (2003) 6545-6558
20. Hetru C., Letsellier L., Oren Z., Hoffmann J.A., and Shai Y. Androctonin, a hydrophilic disulphide-bridged non-haemolytic anti-microbial peptide: a plausible mode of action. Biochem. J. 345 (2000) 653-664
21. Hoskin D.W., and Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta. 1778 (2008) 357-375
22. Hristova K., Dempsey C.E., and White S.H. Structure, location, and lipid perturbations of melittin at the membrane interface. Biophys. J. 60 (2001) 922-930
23. Hui L., Leung K., and Chen H.M. The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res. 22 (2002) 2811-2816
24. Hung S.C., Wang W., Chan S.I., and Chen H.M. Membrane lysis by the antibacterial peptides cecropin B1 and B3: a spin-label electron spin resonance study on phospholipids bilayers. Biophys. J. 77 (1999) 3120-3133
25. Johnstone S.A., Gelmon K., Mayer L.D., Hancock R.E., and Bally M.B. In vitro characterization of the anticancer activity of membrane-active cationic peptides. 1. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anti-Cancer Drug Design 15 (2000) 151-160
26. Kaufmann S.H., and Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256 (2000) 42-49
27. Kleeff J., Ishiwata T., Kumbasar A., Friess H., Buchler M.W., Lander A.D., and Korc M. The cell-surface heparan sulfate proteoglycan regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 102 (1998) 1662-1673
28. Lee H.S., Park C.B., Kim J.M., Jang S.A., Park I.Y., Kim M.S., Cho J.H., and Kim S.C. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 271 (2008) 47-55
29. Leuschner C., and Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr. Pharm. Des. 10 (2004) 2299-2310
30. Li H., Kolluri S.K., Gu J., Dawson M.I., Cao X., Hobbs P.D., Lin B., Chen G.-Q., Lu J.-S., Lin F., Xie Z., Fontana J.A., Reed J.C., and Zhang X.-K. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 289 (2000) 1159-1164
31. Li Y.C., Park S.K., Ye C.W., and Kim Y.N. Elevated levels of cholesterol rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168 (2006) 1107-1118
32. Lichtenstein A., Ganz T., Selested M.E., and Lehrer R.I. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 68 (1986) 1407-1410
33. Lincke C.R., van der Bliek A.M., Schuurhuis G.J., van der Velde-Koerts T., Smit J.J., and Borst P. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 50 (1990) 1779-1785
34. Mäe M., Myrberg H., El-Andaloussi S., and Langel Ü. Design of a tumor homing cell-penetrating peptide for drug delivery. Int. J. Pept. Res. Ther. 15 (2009) 11-15
35. Mai J.C., Mi Z., Kim S.H., Ng B., and Robbins P.D. A proapoptotic peptide for the treatment of solid tumors. Cancer Res. 61 (2001) 7709-7712
36. Makovitzki A., and Shai Y. pH-Dependent antifungal lipopeptides and their plausible mode of action. Biochemistry 44 (2005) 9775-9784
37. Makovitski A., Baram J., and Shai Y. Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self assembly to nanostructures, and a plausible mode of action. Biochemistry 47 (2008) 10630-10636
38. Malina A., and Shai Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem. J. 390 (2005) 695-702
39. Merrifield R.B., Juvvadi P., Anderu D., Ubach J., Boman A., and Boman H.G. Retro and retroenantio analogs of cecropin-melittin hybrids. Proc. Natl. Acad. Sci. USA 92 (1995) 3449-3453
40. Ohsaki Y., Gazdar A.F., and Chen H.C. Antitumor activity of magainin analogues against human cancer cell lines. Cancer Res. 52 (1992) 3534-3538
41. Oren Z., and Shai Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47 (1998) 451-463
42. Ouyang G.-L., Li Q.-F., Peng X.-X., Liu S.-G., and Hong S.-G. Effects of tachyplesin on proliferation and differentiation of human hepatocellular carcinoma SMMC-7721 cells. World J. Gastroenterol. 8 (2002) 1053-1058
43. Pardo J., Perez-Galan P., Gamen S., Marzo I., Monleon I., Kaspar A.A., Susín A.A., Kroemer G., Krensky A.M., Naval J., and Anel A. A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis. J. Immunol. 167 (2001) 1222-1229
44. Park N.G., Lee S., Oishi O., Aoyagi H., Iwanaga S., Yamashita S., and Ohno M. Conformation of tachyplesin I from Tachypleus tridentatus when interacting with lipid matrices. Biochemistry 31 (1992) 1241-1247
45. Peck M.K., Darveau R.P., and Fell H.P. Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides. Cancer Chemother. Pharmacol. 32 (1993) 109-115
46. Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13 (2006) 1859-1876
47. Ruoslahti E., Duza T., and Zhang L. Vascular homing peptides with cell penetrating properties. Curr. Pharm. Des. 11 (2005) 3655-3660
48. Sacchi A., Gasparri A., Curnis F., Bellone M., and Corti A. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res. 64 (2004) 7150-7155
49. Sacchi A., Gasparri A., Gallo-Stampino C., Toma S., Curnis F., and Corti A. Synergistic antitumor activity of cisplatin, paclitaxel and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin. Cancer Res. 12 (2006) 175-182
50. Saini S.S., Chopra A.K., and Peterson J.W. Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells. Toxicon 27 (1999) 1605-1619
51. Shadidi M., and Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Res. Upd. 6 (2003) 363-371
52. Shai Y. Mechanism of the binding, insertion, and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1462 (1999) 55-70
53. Sharma S.V. Melittin resistance: a counterselection for ras transformation. Oncogene 7 (1992) 192-201
54. 2 activity and calcium influx in ras-transformed cells. Oncogene 8 (1993) 938-947
55. Silvestro L., Gupta K., Weiser J.N., and Axelson P.H. The concentration-dependent membrane activity of cecropin A. Biochemistry 36 (1997) 11452-11464
56. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., Derfus A.M., Yang M., Hoffman R.M., Bhatia S., Sailor M.J., and Ruoslahti E. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA 104 (2007) 932-936
57. Simons K., and Ikonen E. How cells handle cholesterol. Science 290 (2000) 1721-1726
58. Smith L.L., Brow K., Carthew P., Lim C.K., Martin E.A., and Styles J. Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit. Rev. Toxicol. 30 (2007) 571-594
59. Steiner H., Andreu D., and Merrifield R.B. Binding and action of cecropin and cecropin analogues: antibacterial peptides from insects. Biochim. Biophys. Acta 939 (1988) 260-266
60. Strom M.B., Haug B.E., Skar M.L., Stensen W., Stiberg T., and Svendsen J.S. The pharmacophore of short cationic antibacterial peptides. J. Med. Chem. 46 (2003) 1567-1570
61. Svensen J., Stensen W., Brandsdal B.O., Haug B.E., Monrad J., and Svensen J.S. Antimicrobial peptides with stability toward tryptic degradation. Biochemistry 47 (2008) 3777-3788
62. Papo N., and Shai Y. New lytic peptides based on the D, L-amphipathic helic motif preferentially kill tumor cells compared to normal cells. Biochemistry 42 (2003) 9346-9354
63. Papo N., and Shai Y. Host defense peptides as new weapons in cancer treatment. Cell. Mol. Life Sci. 62 (2005) 785-790
64. Papo N., Shahar M., Eisenbach L., and Shai Y. A novel lytic peptide composed of D-, L-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. 278 (2003) 21018-21023
65. Park C.B., Yi K.-S., Matsuzaki K., Kim M.S., and Kim S.C. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. USA 97 (2000) 8245-8250
66. Shin S.Y., Kang S.W., Lee D.G., Eom S.H., Song W.K., and Kim J.I. CRAMP analogues having potent antibiotic activity against bacterial, fungal and tumor cells without hemolytic activity. Biochem. Biophys. Res. Commun. 275 (2000) 904-909
67. Srisailam S., Arunkumar A.I., Wang W., Yu C., and Chen H.M. Conformational study of a custom antibacterial peptide cecropin B1: implications of the lytic activity. Biochem. Biophys. Acta 1479 (2000) 275-285
68. Utsugi T., Schroit A.J., Connor J., Buccana C.D., and Fidler I.J. Elevated expression of phosphatidylserine in the outer leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 51 (1991) 3062-3066
69. Wachinger M., Kleinschmidt A., Winder D., von Pechmann N., Ludvigsen A., Neumann M., Holle R., Salomons B., Erfle V., and Brack-Werner R. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J. Gen. Virol. 79 (1998) 731-740
70. Winder D., Gunzburg W.H., Erfle V., and Salmons B. Expression of antimicrobial peptides has an antitumor effect in human cells. Biochem. Biophys. Res. Commun. 242 (1998) 608-612
71. Yang C.Y., Dantzig A.H., and Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharmaceutical Res. 16 (1999) 1331-1343
72. Yoon W.H., Park H.D., Lim K., and Hwang B.D. Effect of O-glycosylated mucin on invasion and metastastis of HM7 human colon cancer cells. Biochem. Biophys. Res. Commun. 222 (1997) 694-699
73. Wade D., Boman A., Wahlin B., Drain C.M., Andreu D., Boman H.G., and Merrifield R.B. All D-amino acid-containing channel forming antibiotic peptides. Proc. Natl. Acad. Sci. USA 87 (1990) 4761-4765
74. Wadia J.S., and Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 13 (2002) 52-56
75. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
76. Zwaal R.F., and Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89 (1997) 1121-1132